Dual inhibitors of matrix metalloproteinases and carbonic anhydrases: Iminodiacetyl-based hydroxamate-benzenesulfonamide conjugates

Journal of Medicinal Chemistry

Volumn 51, Issue 24, 2008, Pages 7968-7979

  Marques, Sérgio M ^a   Nuti, Elisa ^b   Rossello, Armando ^b   Supuran, Claudiu T ^c   Tuccinardi, Tiziano ^b   Martinelli, Adriano ^b   Santos, M Amélia ^a  

^a INSTITUTO SUPERIOR TÉCNICO   (Portugal)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; BENZENESULFONAMIDE DERIVATIVE; BICARBONATE; CARBON DIOXIDE; CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE INHIBITOR; CGS 27023A; DIGLYCINE; HYDROXAMATE BENZENESULFONAMIDE CONJUGATE; HYDROXAMIC ACID; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; N (4 SULFAMOYLPHENYLETHYL) 4 SULFAMOYLBENZAMIDE; UNCLASSIFIED DRUG;

ARTICLE; CANCER THERAPY; CARCINOGENESIS; CATALYSIS; DRUG CONJUGATION; DRUG DESIGN; DRUG SYNTHESIS; ENZYME DEGRADATION; ENZYME INHIBITION; EXTRACELLULAR MATRIX; IN VITRO STUDY; MOLECULAR INTERACTION; MOLECULAR MODEL; NONHUMAN; REGULATORY MECHANISM;

ANOXIA; CARBONIC ANHYDRASES; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INHIBITORY CONCENTRATION 50; MATRIX METALLOPROTEINASES; MODELS, CHEMICAL; MOLECULAR CONFORMATION; PROTEIN BINDING; PROTEIN ISOFORMS; SULFONAMIDES; ZINC;

EID: 58149086406     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800964f     Document Type: Article

References (53)

1. Sternlicht, M. D.; Werb, Z. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol. 2001, 17, 463-516.
2. Egeblad, M.; Werb, Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2002, 2, 161-174.
3. Parks, W. C.; Wilson, C. L.; López-Boado, Y. S. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat. Rev. Immunol. 2004, 4, 617-629.
4. Vartak, D. G.; Gemeinhart, R. A. Matrix metalloproteases: underutilized targets for drug delivery. J. Drug Target. 2007, 15, 1-20.
5. Raffetto, J. D.; Khalil, R. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. A. Biochem. Pharmacol. 2008, 75, 346-359.
6. Overall, C. M.; López-Otín, C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat. Rev. Cancer 2002, 2, 657-672.
7. Martin, M. D.; Matrisian, L. M. The other side of MMPs: protective roles in tumor progression. Cancer Metastasis Rev. 2007, 26, 717-724.
8. Coussens, L. M.; Fingleton, B.; Matrisian, L. M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002, 295, 2387-2392.
9. Overall, C. M.; Kleifeld, O. Tumour microenvironment - Opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat. Rev. Cancer 2006, 6, 227-239.
10. Overall, C. M.; Kleifeld, O. Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Br. J. Cancer 2006, 94, 941-946.
11. Reiter, L. A.; Robinson, R. P.; McClure, K. F.; Jones, C. S.; Reese, M. R.; Mitchell, P. G.; Otterness, I. G.; Bliven, M. L.; Liras, J.; Cortina, S. R.; Donahue, K. M.; Eskra, J. D.; Griffiths, R. J.; Lame, M. E.; Lopez-Anaya, A.; Martinelli, G. J.; McGahee, S. M.; Yocum, S. A.; Lopresti-Morrow, L. L.; Tobiassen, L. M.; Vaughn-Bowser, M. L. Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1. Bioorg. Med. Chem. Lett. 2004, 14, 3389-3395.
12. Fingleton, B. MMPs as therapeutic targets - Still a viable option. Semin. Cell Dev. Biol. 2008, 19, 61-68.
13. Supuran, C. T. Carbonic anhydrases: catalytic and inhibition mechanisms, distribution and physiological roles. In Carbonic Anhydrase. Its Inhibitors and Activators; Supuran, C. T.; Scozzafava, A.; Conway, J., Eds. CRC Press: Boca Raton, London, and New York, 2004; pp 1-23.
14. Maren, T. H. Carbonic anhydrase: chemistry, physiology, and inhibition. Physiol. Rev. 1967, 47, 595-781.
15. Supuran, C. T.; Scozzafava, A.; Casini, A. Carbonic anhydrase inhibitors. Med. Res. Rev. 2003, 23, 146-189.
16. Scozzafava, A.; Mastrolorenzo, A.; Supuran, C. T. Carbonic anhydrase inhibitors and activators and their use in therapy. Expert Opin. Ther. Pat. 2006, 16, 1627-1664.
17. Thiry, A.; Dogné, J.-M.; Masereel, B.; Supuran, C. T. Targeting tumor-associated carbonic anhydrase IX in cancer therapy. Trends Pharmacol. Sci. 2006, 27, 566-573.
18. Supuran, C. T. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat. Rev. Drug Discovery 2008, 7, 168-181.
19. Alterio, V.; Vitale, R. M.; Monti, S. M.; Pedone, C.; Scozzafava, A.; Cecchi, A.; Simone, G. D.; Supuran, C. T. Carbonic anhydrase inhibitors: X-ray and molecular modeling study for the interaction of a fluorescent antitumor sulfonamide with isozyme II and IX. J. Am. Chem. Soc. 2006, 128, 8329-8335.
20. MacPherson, L. J.; Bayburt, E. K.; Capparelli, M. P.; Carroll, B. J.; Goldstein, R.; Justice, M. R.; Zhu, L.; Hu, S.-i.; Melton, R. A.; Fryer, L.; Goldberg, R. L.; Doughty, J. R.; Spirito, S.; Blancuzzi, V.; Wilson, D.; O'Byrne, E. M.; Ganu, V.; Parker, D. T. Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits. J. Med. Chem. 1997, 40, 2525-2532.
21. Mincione, F.; Starnotti, M.; Menabuoni, L.; Scozzafava, A.; Casini, A.; Supuran, C. T. Carbonic anhydrase inhibitors: 4-sulfamoyl-benzenecarboxamides and 4-chloro-3-sulfamoyl-benzenecarboxamides with strong topical antiglaucoma properties. Bioorg. Med. Chem. Lett. 2001, 11, 1787-1791.
22. Scozzafava, A.; Supuran, C. T. Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes. J. Med. Chem. 2000, 43, 3677-3687.
23. Nuti, E.; Orlandini, E.; Nencetti, S.; Rossello, A.; Innocenti, A.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates. Bioorg. Med. Chem. 2007, 15, 2298-2311.
24. Campestre, C.; Tortorella, P.; Agamennone, M.; Preziuso, S.; Biasone, A.; Nuti, E.; Rossello, A.; Gallina, C. Peptidyl 3-substituted 1-hydroxyureas as isosteric analogues of succinylhydroxamate MMP inhibitors. J. Med. Chem. 2008, 43, 1008-1014.
25. Temperini, C.; Innocenti, A.; Scozzafava, A.; Supuran, C. T. N-hydroxyurea - a versatile zinc binding function in the design of metalloenzyme inhibitors. Bioorg. Med. Chem. Lett. 2006, 16, 4316-4320.
26. Gupta, S. P.; Maheswaran, V.; Pande, V.; Kumar, D. A comparative QSAR study on carbonic anhydrase and matrix metalloproteinase inhibition by sulfonylated amino acid hydroxamates. J. Enzyme Inhib. Med. Chem. 2003, 18, 7-13.
27. Santos, M. A.; Marques, S. M.; Tuccinardi, T.; Carelli, P.; Panelli, L.; Rossello, A. Design, synthesis and molecular modeling studies of iminodiacetyl monohydroxamic acid derivatives as MMP inhibitors. Bioorg. Med. Chem. 2006, 14, 7539-7550.
28. Khalifah, R. G. The carbon dioxide hydration activity of carbonic anhydrase. J. Biol. Chem. 1971, 246, 2561-2573.
29. Marques, S. M.; Chaves, S.; Rossello, A.; Tuccinardi, T.; Santos, M. A. Iminodiacetyl-monohydroxamate derivatives as potent and selective MMP inhibitors. Met. Ions Biol. Med. 2006, 9, 117-121.
30. Bairoch, A.; Apweiler, R. The SWISS-PROT protein sequence database and its supplement TrEMBL in 2000. Nucleic Acids Res. 2000, 28, 45-48.
31. Yoshiizumi, K.; Yamamoto, M.; Miyasaka, T.; Ito, Y.; Kumihara, H.; Sawa, M.; Kiyoi, T.; Yamamoto, T.; Nakajima, F.; Hirayama, R.; Kondo, H.; Ishibushi, E.; Ohmoto, H.; Inoue, Y.; Yoshino, K. Synthesis and structure-activity relationships of 5,6,7,8-tetrahydropyrido(3,4-b)pyrazine-based hydroxamic acids as HB-EGF shedding inhibitors. Bioorg. Med. Chem. 2003, 11, 433-450.
32. Tuccinardi, T.; Martinelli, A.; Nuti, E.; Carelli, P.; Balsano, F.; Uccello-Barretta, G.; Murphy, G.; Rossello, A. Amber force field implementation, molecular modelling study, synthesis and MMP-1/MMP-2 inhibition profile of (R)- and (S)-N-hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3-methylbutanamides. Bioorg. Med. Chem. 2006, 14, 4260-4276.
33. Peng, S. X.; Strojnowski, M. J.; Joanna K, Hu, B. J. S.; Eichhold, T. H.; Wehmeyer, K. R.; Pikul, S.; Almstead, N. G. Gas chromatographic-mass spectrometric analysis of hydroxylamine for monitoring the metabolic hydrolysis of metalloprotease inhibitors in rat and human liver microsomes. J. Chromatogr. B 1999, 724, 181-187.
34. Terp, G. E.; Cruciani, G.; Christensen, I. T.; Jørgensen, F. S. Structural differences of matrix metalloproteinases with potential implications for inhibitor selectivity examined by the GRID/CPCA approach. J. Med. Chem. 2002, 45, 2675-2684.
35. Levin, J. I.; Chen, J. M.; Cheung, K.; Cole, D.; Crago, C.; Santos, E. D.; Du, X.; Khafizova, G.; MacEwan, G.; Niu, C.; Salaski, E. J.; Zask, A.; Cummons, T.; Sung, A.; J. Xu, Y. Z.; Xu, W.; Ayral-Kaloustian, S.; Jin, G.; Cowling, R.; Barone, D.; Mohler, K. M.; Black, R. A.; Skotnicki, J. S. Acetylenic TACE inhibitors. Part 1. SAR of the acyclic sulfonamide hydroxamates. Bioorg. Med. Chem. Lett. 2003, 13, 2799-2803.
36. Rao, B. G.; Bandarage, U. K.; Wang, T.; Come, J. H.; Perola, E.; Wei, Y.; Tian, S.-K.; Saunders, J. O. Novel thiol-based TACE inhibitors: Rational design, synthesis, and SAR of thiol-containing aryl sulfonamides. Bioorg. Med. Chem. Lett. 2007, 17, 2250-2253.
37. Santos, M. A.; Marques, S.; Vullo, D.; Innocenti, A.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors. Inhibition of cytosolic/ tumor-associated isoforms I, II and IX with iminodiacetic carboxylates/ hydroxamates also incorporating benzenesulfonamide moieties. Bioorg. Med. Chem. Lett. 2007, 17, 1538-1543.
38. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267, 727-748.
39. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The Protein Data Bank. Nucleic Acids Res. 2000, 28, 235-242.
40. Tuccinardi, T.; Nuti, E.; Ortore, G.; Rossello, A.; Avramova, S. I.; Martinelli, A. Development of a receptor-based 3D-QSAR study for the analysis of MMP2, MMP3, and MMP9 inhibitors. Bioorg. Med. Chem. 2008, 16, 7749-7758.
41. Armarego, W. L. F.; Perrin, D. D. Purification of Laboratory Chemicals, 4th ed.; Butterworth-Heinemann: Oxford, 1999.
42. Knight, C. G.; Willenbrock, F.; Murphy, G. A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases. FEBS Lett. 1992, 296, 263-266.
43. Murphy, G.; Crabbe, T. Gelatinases A and B. Methods Enzymol. 1995, 248, 470-484.
44. 2, a fluorogenic substrate with increased specificity constants for collagenases and tumor necrosis factor converting enzyme. Anal. Biochem. 2004, 328, 166-173.
45. SoftMax Pro 4.7.1 by Molecular Device.
46. GraFit version 4 by Erithecus Software.
47. (a) Cecchi, A.; Hulikova, A.; Pastorek, J.; Pastorekova, S.; Scozzafava, A.; Winum, J.-Y.; Montero, J.-L.; Supuran, C. T. Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors. J. Med. Chem. 2005, 48, 4834-4841.
48. (b) Casey, J. R.; Morgan, P. E.; Vullo, D.; Scozzafava, A.; Mastrolorenzo, A.; Supuran, C. T. Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX. J. Med. Chem. 2004, 47, 2337-2347.
49. (a) Pastorekova, S.; Casini, A.; Scozzafava, A.; Vullo, D.; Pastorek, J.; Supuran, C. T. Carbonic anhydrase inhibitors: the first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX. Bioorg. Med. Chem. Lett. 2004, 14, 869-873.
50. (b) Vullo, D.; Innocenti, A.; Nishimori, I.; Pastorek, J.; Scozzafava, A.; Pastorekova, S.; Supuran, C. T. Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides - a new target for the design of antitumor and antiglaucoma drugs? Bioorg. Med. Chem. Lett. 2005, 15, 963-969.
51. Maestro, version 7.5; Schrödinger Inc.: Portland, OR, 2005.
52. Macromodel, version 8.5; Schrödinger Inc.: Portland, OR, 1999.
53. Pettersen, E. F.; Goddard, T. D.; Huang, C. C.; Couch, G. S.; Greenblatt, D. M.; Meng, E. C.; Ferrin, T. E. UCSF Chimera - A visualization system for exploratory research and analysis. J. Comput. Chem. 2004, 25, 1605-1612.